BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38409200)

  • 1. Serum amyloid A promotes glycolysis of neutrophils during PD-1 blockade resistance in hepatocellular carcinoma.
    He M; Liu Y; Chen S; Deng H; Feng C; Qiao S; Chen Q; Hu Y; Chen H; Wang X; Jiang X; Xia X; Zhao M; Lyu N
    Nat Commun; 2024 Feb; 15(1):1754. PubMed ID: 38409200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
    Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
    J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma.
    Deng H; Kan A; Lyu N; He M; Huang X; Qiao S; Li S; Lu W; Xie Q; Chen H; Lai J; Chen Q; Jiang X; Liu S; Zhang Z; Zhao M
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34168004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma.
    Zhang W; Liu Y; Yan Z; Yang H; Sun W; Yao Y; Chen Y; Jiang R
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modified Biejia Jianwan decoction restrains PD-L1-mediated immune evasion through the HIF-1α/STAT3/NF-κB signaling pathway.
    Tian X; Liu F; Wang Z; Zhang J; Liu Q; Zhang Y; Zhang D; Huang C; Zhao J; Jiang S
    J Ethnopharmacol; 2024 Mar; 322():117577. PubMed ID: 38104877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model.
    Liu H; Shen J; Lu K
    Biochem Biophys Res Commun; 2017 Apr; 486(2):239-244. PubMed ID: 28254435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HSF1 is involved in immunotherapeutic response through regulating APOJ/STAT3-mediated PD-L1 expression in hepatocellular carcinoma.
    Cheng H; Wang S; Huang A; Ma J; Gao D; Li M; Chen H; Guo K
    Cancer Biol Ther; 2023 Dec; 24(1):1-9. PubMed ID: 36482717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KDM1A Promotes Immunosuppression in Hepatocellular Carcinoma by Regulating PD-L1 through Demethylating MEF2D.
    Wang Y; Cao K
    J Immunol Res; 2021; 2021():9965099. PubMed ID: 34307695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation.
    Du SS; Chen GW; Yang P; Chen YX; Hu Y; Zhao QQ; Zhang Y; Liu R; Zheng DX; Zhou J; Fan J; Zeng ZC
    Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1243-1255. PubMed ID: 34986380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blocking Triggering Receptor Expressed on Myeloid Cells-1-Positive Tumor-Associated Macrophages Induced by Hypoxia Reverses Immunosuppression and Anti-Programmed Cell Death Ligand 1 Resistance in Liver Cancer.
    Wu Q; Zhou W; Yin S; Zhou Y; Chen T; Qian J; Su R; Hong L; Lu H; Zhang F; Xie H; Zhou L; Zheng S
    Hepatology; 2019 Jul; 70(1):198-214. PubMed ID: 30810243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Over-Expression of GUSB Leads to Primary Resistance of Anti-PD1 Therapy in Hepatocellular Carcinoma.
    Kong X; Zheng Z; Song G; Zhang Z; Liu H; Kang J; Sun G; Sun G; Huang T; Li X; Rong D; Wang K; Tang W; Xia Y
    Front Immunol; 2022; 13():876048. PubMed ID: 35812439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aucubin enhances the antitumor activity of cisplatin through the inhibition of PD-L1 expression in hepatocellular carcinoma.
    Gao ZX; Zhang ZS; Qin J; Zhang MZ; Cao JL; Li YY; Wang MQ; Hou LL; Fang D; Xie SQ
    Phytomedicine; 2023 Apr; 112():154715. PubMed ID: 36821999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline and early changes in circulating Serum Amyloid A (SAA) predict survival outcomes in advanced non-small cell lung cancer patients treated with Anti-PD-1/PD-L1 monotherapy.
    He LN; Fu S; Zhang X; Hu Q; Du W; Li H; Chen T; Chen C; Jiang Y; Zhou Y; Lin Z; Yang Y; Huang Y; Zhao H; Fang W; Zhang L; Hong S
    Lung Cancer; 2021 Aug; 158():1-8. PubMed ID: 34087538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of GSDMD sensitizes HCC to anti-PD-1 by activating cGAS pathway and downregulating PD-L1 expression.
    Lv T; Xiong X; Yan W; Liu M; Xu H; He Q
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-derived PD1 and PD-L1 could promote hepatocellular carcinoma growth through autophagy induction in vitro.
    Chen Z; Liu S; Xie P; Zhang B; Yu M; Yan J; Jin L; Zhang W; Zhou B; Li X; Xiao Y; Xu Y; Ye Q; Li H; Guo L
    Biochem Biophys Res Commun; 2022 May; 605():82-89. PubMed ID: 35316767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma.
    Liu J; Liu Y; Meng L; Liu K; Ji B
    Oncol Rep; 2017 Aug; 38(2):899-907. PubMed ID: 28627705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1-Mediated Immunosuppression in Hepatocellular Carcinoma: Relationship with Macrophages Infiltration and Inflammatory Response Activity.
    Guo S; Wang X; Zhou H; Gao Y; Wang P; Zhi H; Sun Y; Zhang Y; Gan J; Xiao Y; Ning S
    Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.